An exam can guide the next choice

The exam helps narrow where your soreness begins

The doctor may ask where the ache travels and which movements make it worse. You can expect time to explain what has changed.

The exam may check your strength, feeling, balance and the way you walk. Those checks help the doctor decide what care fits the cause.

An X-ray can help show whether a fall injured a bone. Another scan may help when new weakness suggests pressure on a nerve.

Medicine may help briefly, but your health history matters

Even familiar medicine may upset your stomach or affect your kidneys, heart or other pills. It’s wise to ask your regular doctor before changing what you take.

Medicine may help you sleep or move while the back is especially sore. It won’t tell you why the ache began.

If you feel dizzy or sick after taking it, please call the person who advised it. You’re always welcome to stop and ask a question.

The doctor should say when treatment will be checked

Before a procedure, ask what it is meant to change. The doctor can tell you when your walking, sleep or daily work will be checked again.

You may also ask about recovery, repeat visits and your likely cost. There’s no need to hurry through those questions.

At home, you can note the daily task that soreness makes hardest. QC Kinetix has licensed medical staff who can review non-surgical regenerative care, including PRP; a blood sample is spun until it holds more platelets, then the prepared fluid is put into the sore part of your back.

Sources

1. A meta-analysis of 35 placebo-controlled randomised trials found NSAIDs reduce spinal pain and disability, but by an amount below the threshold for clinical importance: six people must be treated with an NSAID rather than placebo for one additional person to achieve clinically important pain reduction, and NSAIDs raised the risk of gastrointestinal reactions 2.5-fold. The authors conclude that no simple analgesic provides clinically important effects for spinal pain over placebo.

   Machado GC, Maher CG, Ferreira PH, et al. — Non-steroidal anti-inflammatory drugs for spinal pain: a systematic review and meta-analysis.. Annals of the Rheumatic Diseases, 2017. DOI: 10.1136/annrheumdis-2016-210597.

2. High-quality evidence from 13 randomised trials shows paracetamol (acetaminophen) is INEFFECTIVE for low back pain: the weighted mean difference against placebo was -0.5 points on a 0-100 pain scale, with no effect on disability or quality of life, and patients taking it were nearly four times more likely to have abnormal liver function tests.

   Machado GC, Maher CG, Ferreira PH, et al. — Efficacy and safety of paracetamol for spinal pain and osteoarthritis: systematic review and meta-analysis of randomised placebo controlled trials.. BMJ, 2015. DOI: 10.1136/bmj.h1225.

3. A meta-analysis of 31 trials and 6,505 participants found very low-certainty evidence that non-benzodiazepine antispasmodic muscle relaxants reduce acute low back pain by 7.7 points on a 0-100 scale at two weeks or less - not clinically important - with no effect on disability and a 1.6-fold increase in adverse events. The authors describe considerable uncertainty about both efficacy and safety.

   Cashin AG, Folly T, Bagg MK, et al. — Efficacy, acceptability, and safety of muscle relaxants for adults with non-specific low back pain: systematic review and meta-analysis.. BMJ, 2021. DOI: 10.1136/bmj.n1446.

4. A meta-analysis of 33 trials and 5,318 participants found moderate-certainty evidence that SNRI antidepressants reduce back pain by 5.3 points on a 0-100 scale at 3-13 weeks - small and NOT clinically important - and that tricyclics did not reduce back pain or disability at all. SNRIs and tricyclics may help sciatica, but that evidence is low to very low certainty.

   Ferreira GE, McLachlan AJ, Lin CC, et al. — Efficacy and safety of antidepressants for the treatment of back pain and osteoarthritis: systematic review and meta-analysis.. BMJ, 2021. DOI: 10.1136/bmj.m4825.

5. The SPACE trial randomised 240 patients with moderate-to-severe chronic back pain or hip/knee osteoarthritis pain to an opioid or a non-opioid medication strategy for 12 months. Opioids were not superior on pain-related function, pain intensity was significantly BETTER in the non-opioid group, and medication-related adverse symptoms were significantly more common with opioids. The authors state the results do not support initiating opioid therapy for chronic back pain.

   Krebs EE, Gravely A, Nugent S, et al. — Effect of Opioid vs Nonopioid Medications on Pain-Related Function in Patients With Chronic Back Pain or Hip or Knee Osteoarthritis Pain: The SPACE Randomized Clinical Trial.. JAMA, 2018. DOI: 10.1001/jama.2018.0899.

6. The OPAL trial randomised 347 people presenting with acute low back or neck pain to guideline care plus a short course of oxycodone-naloxone or guideline care plus an identical placebo. Mean pain at six weeks was 2.78 in the opioid group versus 2.25 in the placebo group - the opioid group did slightly WORSE, and the difference was not statistically significant. The authors call for a change in the frequent use of opioids for these conditions.

   Jones CMP, Day RO, Koes BW, et al. — Opioid analgesia for acute low back pain and neck pain (the OPAL trial): a randomised placebo-controlled trial.. The Lancet, 2023. DOI: 10.1016/S0140-6736(23)00404-X.

7. A multicentre randomised trial assigned 169 surgical candidates with symptomatic lumbar spinal stenosis to surgical decompression or physical therapy. Mean physical-function improvement at two years was 22.4 with surgery and 19.2 with physical therapy, with no significant difference between groups - and this despite 57% of the physical-therapy group crossing over to surgery. The authors call for shared decision-making with full disclosure of the non-surgical evidence.

   Delitto A, Piva SR, Moore CG, et al. — Surgery versus nonsurgical treatment of lumbar spinal stenosis: a randomized trial.. Annals of Internal Medicine, 2015. DOI: 10.7326/M14-1420.

8. A multicentre randomised trial of 103 patients with chronic sacroiliac joint pain compared minimally invasive sacroiliac fusion with structured conservative management. At 12 months, low back pain improved by 41.6 VAS points after fusion versus 14.0 with conservative management, and ODI improved by 25.0 versus 8.7. The trial was NOT blinded, its outcomes were self-assessed, and complications included one nerve impingement, one haematoma and two cases of recurrent pain attributed to possible device loosening.

   Dengler JD, Kools D, Pflugmacher R, et al. — 1-Year Results of a Randomized Controlled Trial of Conservative Management vs. Minimally Invasive Surgical Treatment for Sacroiliac Joint Pain.. Pain Physician, 2017.

9. The FDA states verbatim that stem cell products, stromal vascular fraction, umbilical cord blood, Wharton's jelly, amniotic fluid and exosome products have NOT been 'approved for the treatment of any orthopedic condition, such as osteoarthritis, tendonitis, disc disease, tennis elbow, back pain, hip pain, knee pain, neck pain, or shoulder pain.' No stem cell product is approved in the United States for any orthopedic use: the only ones with FDA approval at all are blood-forming cells derived from umbilical cord blood, approved solely for disorders of blood production, and there are currently no FDA-approved exosome products.

   U.S. Food and Drug Administration — Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes.. FDA.gov, 2025.